SCHEMBL5777820

SCHEMBL5777820

COc1cc(/C=N/Nc2ccc(-c3cnco3)cc2)ccc1O

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MPO P05164 4/20 0.61
GAA P10253 10/20 0.58
MAPT P10636 9/20 0.58
RAB9A P51151 5/20 0.58
SMN1; SMN2 Q16637 3/20 0.58
KDM4E B2RXH2 3/20 0.58
NPC1 O15118 3/20 0.58
POLB P06746 1/20 0.58
APEX1 P27695 1/20 0.58
CASP6 P55212 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
KMT2A Q03164 4/20 0.50
MEN1 O00255 3/20 0.50
LMNA P02545 1/20 0.50
GFER P55789 2/20 0.48
GSK3B P49841 1/20 0.47
ALDH1A1 P00352 1/20 0.47
PKM P14618 1/20 0.47
ATM Q13315 1/20 0.47
NT5E P21589 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5777823 1.00 MPO (0.61) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5775898 0.93 MPO (0.61) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5775893 0.93 MPO (0.61) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5774744 0.90 MAPT (0.55) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5774746 0.90 MAPT (0.55) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5777110 0.85 RAB9A (0.45) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5777108 0.85 RAB9A (0.45) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5780484 0.85 MAPT (0.47) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5780488 0.85 MAPT (0.47) MPOGAAMAPTRAB9ASMN1; SMN2
SCHEMBL5777825 0.81 NPC1 (0.45) GAAMAPTRAB9ASMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed
EP-1612204-A1 HYDRAZONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-01-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT MPO 2642/4885GAA 3175/4885MAPT 94/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.